IL135584A - Use of dual, non-selective antagonists ß-adrenoreceptor and α1-adrenoreceptor in the preparation of a drug for the treatment of amyloid diseases - Google Patents

Use of dual, non-selective antagonists ß-adrenoreceptor and α1-adrenoreceptor in the preparation of a drug for the treatment of amyloid diseases

Info

Publication number
IL135584A
IL135584A IL13558498A IL13558498A IL135584A IL 135584 A IL135584 A IL 135584A IL 13558498 A IL13558498 A IL 13558498A IL 13558498 A IL13558498 A IL 13558498A IL 135584 A IL135584 A IL 135584A
Authority
IL
Israel
Prior art keywords
carbon atoms
hydrogen
adrenoceptor
lower alkyl
selective
Prior art date
Application number
IL13558498A
Other languages
English (en)
Hebrew (he)
Other versions
IL135584A0 (en
Original Assignee
Boehringer Mannheim Pharm Corp
Smithkline Beecham Corp Ltd Pa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp, Smithkline Beecham Corp Ltd Pa filed Critical Boehringer Mannheim Pharm Corp
Publication of IL135584A0 publication Critical patent/IL135584A0/xx
Publication of IL135584A publication Critical patent/IL135584A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13558498A 1997-10-15 1998-10-15 Use of dual, non-selective antagonists ß-adrenoreceptor and α1-adrenoreceptor in the preparation of a drug for the treatment of amyloid diseases IL135584A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6236697P 1997-10-15 1997-10-15
PCT/US1998/021789 WO1999018794A1 (en) 1997-10-15 1998-10-15 Method for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
IL135584A0 IL135584A0 (en) 2001-05-20
IL135584A true IL135584A (en) 2005-12-18

Family

ID=22042015

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13558498A IL135584A (en) 1997-10-15 1998-10-15 Use of dual, non-selective antagonists ß-adrenoreceptor and α1-adrenoreceptor in the preparation of a drug for the treatment of amyloid diseases

Country Status (16)

Country Link
US (1) US6358990B1 (ko)
EP (1) EP1024697A4 (ko)
JP (1) JP2001519364A (ko)
KR (1) KR100573352B1 (ko)
CN (1) CN1281334A (ko)
AU (1) AU751526B2 (ko)
BR (1) BR9814075A (ko)
CA (1) CA2305262A1 (ko)
HU (1) HUP0100024A3 (ko)
IL (1) IL135584A (ko)
NO (1) NO20001869L (ko)
NZ (1) NZ504419A (ko)
PL (1) PL339910A1 (ko)
TR (1) TR200001018T2 (ko)
WO (1) WO1999018794A1 (ko)
ZA (1) ZA989365B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142175A1 (de) * 2001-10-09 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung von ß-Adrenozeptor-Agonisten zur Behandlung von neurodegenerativen Erkrankungen
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
EP1539140A4 (en) * 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
BR0312102A (pt) * 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
CN1991364A (zh) * 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
DK2247558T3 (da) 2008-02-14 2022-02-21 Lilly Co Eli Nye billeddannelsesmidler til detektering af neurologisk dysfunktion
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
CN103172643B (zh) * 2011-12-26 2016-03-02 中国医学科学院药物研究所 黄皮咔唑生物碱及其制备方法和其药物组合物与用途
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
EP3013342B1 (en) 2013-06-27 2021-04-14 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
US20230381139A1 (en) * 2020-09-17 2023-11-30 Uti Limited Partnership Methods of treating and/or preventing alzheimer’s disease with r-carvedilol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
PH25025A (en) * 1986-12-17 1991-01-28 Glaxo Group Ltd A method of treating dementia and other cognitive disorders using 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazol-4-one
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US4983608A (en) * 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
JPH0558998A (ja) * 1991-09-06 1993-03-09 Taisho Pharmaceut Co Ltd カルバゾール誘導体
CN1166169A (zh) * 1994-07-27 1997-11-26 三共株式会社 用作毒蕈碱性受体别构效应物的杂环化合物
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
EP1110945A3 (en) * 1995-05-01 2003-05-07 University Of Pittsburgh Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Also Published As

Publication number Publication date
NZ504419A (en) 2002-11-26
TR200001018T2 (tr) 2000-08-21
JP2001519364A (ja) 2001-10-23
ZA989365B (en) 1999-04-15
CN1281334A (zh) 2001-01-24
EP1024697A1 (en) 2000-08-09
AU1089799A (en) 1999-05-03
KR100573352B1 (ko) 2006-04-25
WO1999018794A1 (en) 1999-04-22
EP1024697A4 (en) 2007-05-02
NO20001869L (no) 2000-06-14
CA2305262A1 (en) 1999-04-22
HUP0100024A3 (en) 2002-12-28
KR20010031108A (ko) 2001-04-16
US6358990B1 (en) 2002-03-19
BR9814075A (pt) 2000-09-26
IL135584A0 (en) 2001-05-20
HUP0100024A2 (hu) 2001-07-30
PL339910A1 (en) 2001-01-15
AU751526B2 (en) 2002-08-22
NO20001869D0 (no) 2000-04-11

Similar Documents

Publication Publication Date Title
AU751526B2 (en) Method for treating Alzheimer's disease
KR100386229B1 (ko) 히드록시카르바졸화합물의평활근유주및증식의억제
US7786174B2 (en) Methods and compounds for inhibiting amyloid deposits
US11325904B2 (en) Tropinol esters and related compounds to promote normal processing of APP
NO20171934A1 (en) Compositions and methods of treating a neurodegenerative disease
JP2002226401A (ja) うつ病の併用療法
JP4415075B2 (ja) 炎症性腸疾患のためのカッパーアヘン製剤作働薬
AU2018220521A1 (en) Compounds and methods for treatment of primary biliary cholangitis
US5945448A (en) Brain edema inhibitor
US6096777A (en) Method for inhibiting the expression of Fas
CA2557758C (en) Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
MXPA00003770A (en) Method for treating alzheimer's disease
US20090253765A1 (en) Angiogenesis Inhibitor Containing Amine Derivative as Active Ingredient
CZ20001310A3 (cs) Lék pro léčbu onemocnění způsobených amyloidem
JP2004262812A (ja) 眼圧低下剤
WO2020203822A1 (ja) 血管新生を伴う網膜疾患の治療又は予防のための併用医薬
AU2016333995A1 (en) Methods for treating synovial sarcoma
JP2000007568A (ja) 神経栄養因子様作用剤
JP2003113085A (ja) 神経栄養因子様作用剤
JPH09316002A (ja) 眼疾患用薬剤
JPWO2010047369A1 (ja) 糖尿病性腎症の治療剤
MXPA99001774A (en) Method for inhibiting the expression of fas
AU3512701A (en) Method for inhibiting the expression of FAS
AU2008229759A1 (en) Methods and compounds for inhibiting amyloid deposits
JP2005154320A (ja) 眼疾患治療薬

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees